Loading…
Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children
The Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could us...
Saved in:
Published in: | Italian journal of pediatrics 2021-09, Vol.47 (1), p.181-181, Article 181 |
---|---|
Main Authors: | , , , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03 |
---|---|
cites | cdi_FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03 |
container_end_page | 181 |
container_issue | 1 |
container_start_page | 181 |
container_title | Italian journal of pediatrics |
container_volume | 47 |
creator | Santangelo, Luisa Netti, Giuseppe Stefano Torres, Diletta Domenica Piscopo, Giovanni Carbone, Vincenza Losito, Luciana Milella, Leonardo Lasorella, Maria Luigia Conti, Pasquale Gagliardi, Delio Chironna, Maria Spadaccino, Federica Bresin, Elena Trabacca, Antonio Ranieri, Elena Giordano, Mario |
description | The Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could usually regress after Eculizumab infusion. In contrast, peripheral nervous system (PNS) manifestations in typical HUS are very rare and, when occurring, they require a careful management of neurological sequelae and an intensive multidisciplinary neuro-rehabilitation program.
Here, we present two pediatric cases of severe and complicated typical HUS with PNS manifestations who required therapeutic treatment and an intensive multidisciplinary neuro-rehabilitation program. In both cases, PNS manifestations were followed by the recovery from typical HUS-related severe central neurological damage and manifested mainly with marked bilateral motor deficit and hyporeflexia/areflexia in the lower limbs. The peripheral polyneuropathy was treated with immunosuppressive therapy (methylprednisolone boluses, i.v. immunoglobulins, plasma exchange), followed by a prolonged intensive neuro-rehabilitation program. After 8 months of rehabilitation, both patients gained complete functional recovery.
PNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery. |
doi_str_mv | 10.1186/s13052-021-01133-1 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_730ffbe2a17a4d56ba88e2904bdb57a1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_730ffbe2a17a4d56ba88e2904bdb57a1</doaj_id><sourcerecordid>2574490557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03</originalsourceid><addsrcrecordid>eNpdkk1rFTEUhgdRbK3-ARcScONmaj4mH3cjSKlaKCjYfcgkJ3dymUmuyUzp_fdmemtpXZ1w8ubhnDdv07wn-JwQJT4XwjCnLaakxYQw1pIXzSlRtGslVerlk_NJ86aUHcaMckFeNyes65RSjJw2d78gh_0A2YwoQr5NS0HlUGaY0GRi8FBmM4cUC0oe_R7C1qA53YXY7nNyiw1xiy7PkU1jaEOsDXBoMDCl8TAHi5YMUy3lEF1OE6AQkR3C6DLEt80rb8YC7x7qWXPz7fLm4kd7_fP71cXX69ZywebWdlJYqrwEJjfeOs8dtx4YZj3rJcNKCW8oBSNYTyk1VCop1aZKCfUes7Pm6oh1yez0PofJ5INOJuj7RspbbXIddQRdad73QA2RpnNc9EYpoBvc9a7n0pDK-nJk7Zd-AmchztW2Z9DnNzEMeptuteoolWId5tMDIKc_S7VWT6FYGEcToRqvKZf1I4lQq_Tjf9JdWnKsTq2qrttgzmVV0aPK5lRKBv84DMF6zYg-ZkTXjOj7jOh1jQ9P13h88i8U7C8Or7pO</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2574490557</pqid></control><display><type>article</type><title>Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Santangelo, Luisa ; Netti, Giuseppe Stefano ; Torres, Diletta Domenica ; Piscopo, Giovanni ; Carbone, Vincenza ; Losito, Luciana ; Milella, Leonardo ; Lasorella, Maria Luigia ; Conti, Pasquale ; Gagliardi, Delio ; Chironna, Maria ; Spadaccino, Federica ; Bresin, Elena ; Trabacca, Antonio ; Ranieri, Elena ; Giordano, Mario</creator><creatorcontrib>Santangelo, Luisa ; Netti, Giuseppe Stefano ; Torres, Diletta Domenica ; Piscopo, Giovanni ; Carbone, Vincenza ; Losito, Luciana ; Milella, Leonardo ; Lasorella, Maria Luigia ; Conti, Pasquale ; Gagliardi, Delio ; Chironna, Maria ; Spadaccino, Federica ; Bresin, Elena ; Trabacca, Antonio ; Ranieri, Elena ; Giordano, Mario</creatorcontrib><description>The Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could usually regress after Eculizumab infusion. In contrast, peripheral nervous system (PNS) manifestations in typical HUS are very rare and, when occurring, they require a careful management of neurological sequelae and an intensive multidisciplinary neuro-rehabilitation program.
Here, we present two pediatric cases of severe and complicated typical HUS with PNS manifestations who required therapeutic treatment and an intensive multidisciplinary neuro-rehabilitation program. In both cases, PNS manifestations were followed by the recovery from typical HUS-related severe central neurological damage and manifested mainly with marked bilateral motor deficit and hyporeflexia/areflexia in the lower limbs. The peripheral polyneuropathy was treated with immunosuppressive therapy (methylprednisolone boluses, i.v. immunoglobulins, plasma exchange), followed by a prolonged intensive neuro-rehabilitation program. After 8 months of rehabilitation, both patients gained complete functional recovery.
PNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery.</description><identifier>ISSN: 1824-7288</identifier><identifier>ISSN: 1720-8424</identifier><identifier>EISSN: 1824-7288</identifier><identifier>DOI: 10.1186/s13052-021-01133-1</identifier><identifier>PMID: 34488831</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Anemia ; Anti-Inflammatory Agents - therapeutic use ; Basal ganglia ; Blood pressure ; Case Report ; Child ; Child, Preschool ; Coma ; Creatinine ; Diarrhea ; E coli ; Eculizumab ; Electroencephalography ; Enterohemorrhagic Escherichia Coli ; Escherichia coli Infections ; Female ; Hemolytic uremic syndrome ; Hemolytic-Uremic Syndrome - complications ; Hemolytic-Uremic Syndrome - therapy ; Humans ; Hypokalemia ; Hypoxia ; Immunoglobulins ; Immunoglobulins, Intravenous - therapeutic use ; Immunosuppressive agents ; Infectious diseases ; Laboratories ; Methylprednisolone ; Methylprednisolone - therapeutic use ; Nephrology ; Nervous system ; Neurological complications ; Neurological Rehabilitation ; Neurorehabilitation ; Neutrophils ; Patients ; Pediatrics ; Peripheral nervous system ; Plasma Exchange ; Polyneuropathies - etiology ; Polyneuropathies - therapy ; Polyneuropathy ; Potassium ; Recovery of function ; Rehabilitation ; Renal replacement therapy ; Shiga toxin ; Shiga-Toxigenic Escherichia coli ; Streptococcus infections ; Substantia alba ; Thrombocytopenia ; Ventilators ; Visual impairment</subject><ispartof>Italian journal of pediatrics, 2021-09, Vol.47 (1), p.181-181, Article 181</ispartof><rights>2021. The Author(s).</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03</citedby><cites>FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03</cites><orcidid>0000-0003-3495-2707</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8422760/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2574490557?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,25734,27905,27906,36993,36994,44571,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34488831$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Santangelo, Luisa</creatorcontrib><creatorcontrib>Netti, Giuseppe Stefano</creatorcontrib><creatorcontrib>Torres, Diletta Domenica</creatorcontrib><creatorcontrib>Piscopo, Giovanni</creatorcontrib><creatorcontrib>Carbone, Vincenza</creatorcontrib><creatorcontrib>Losito, Luciana</creatorcontrib><creatorcontrib>Milella, Leonardo</creatorcontrib><creatorcontrib>Lasorella, Maria Luigia</creatorcontrib><creatorcontrib>Conti, Pasquale</creatorcontrib><creatorcontrib>Gagliardi, Delio</creatorcontrib><creatorcontrib>Chironna, Maria</creatorcontrib><creatorcontrib>Spadaccino, Federica</creatorcontrib><creatorcontrib>Bresin, Elena</creatorcontrib><creatorcontrib>Trabacca, Antonio</creatorcontrib><creatorcontrib>Ranieri, Elena</creatorcontrib><creatorcontrib>Giordano, Mario</creatorcontrib><title>Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children</title><title>Italian journal of pediatrics</title><addtitle>Ital J Pediatr</addtitle><description>The Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could usually regress after Eculizumab infusion. In contrast, peripheral nervous system (PNS) manifestations in typical HUS are very rare and, when occurring, they require a careful management of neurological sequelae and an intensive multidisciplinary neuro-rehabilitation program.
Here, we present two pediatric cases of severe and complicated typical HUS with PNS manifestations who required therapeutic treatment and an intensive multidisciplinary neuro-rehabilitation program. In both cases, PNS manifestations were followed by the recovery from typical HUS-related severe central neurological damage and manifested mainly with marked bilateral motor deficit and hyporeflexia/areflexia in the lower limbs. The peripheral polyneuropathy was treated with immunosuppressive therapy (methylprednisolone boluses, i.v. immunoglobulins, plasma exchange), followed by a prolonged intensive neuro-rehabilitation program. After 8 months of rehabilitation, both patients gained complete functional recovery.
PNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery.</description><subject>Anemia</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Basal ganglia</subject><subject>Blood pressure</subject><subject>Case Report</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Coma</subject><subject>Creatinine</subject><subject>Diarrhea</subject><subject>E coli</subject><subject>Eculizumab</subject><subject>Electroencephalography</subject><subject>Enterohemorrhagic Escherichia Coli</subject><subject>Escherichia coli Infections</subject><subject>Female</subject><subject>Hemolytic uremic syndrome</subject><subject>Hemolytic-Uremic Syndrome - complications</subject><subject>Hemolytic-Uremic Syndrome - therapy</subject><subject>Humans</subject><subject>Hypokalemia</subject><subject>Hypoxia</subject><subject>Immunoglobulins</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Immunosuppressive agents</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Methylprednisolone</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Nephrology</subject><subject>Nervous system</subject><subject>Neurological complications</subject><subject>Neurological Rehabilitation</subject><subject>Neurorehabilitation</subject><subject>Neutrophils</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Peripheral nervous system</subject><subject>Plasma Exchange</subject><subject>Polyneuropathies - etiology</subject><subject>Polyneuropathies - therapy</subject><subject>Polyneuropathy</subject><subject>Potassium</subject><subject>Recovery of function</subject><subject>Rehabilitation</subject><subject>Renal replacement therapy</subject><subject>Shiga toxin</subject><subject>Shiga-Toxigenic Escherichia coli</subject><subject>Streptococcus infections</subject><subject>Substantia alba</subject><subject>Thrombocytopenia</subject><subject>Ventilators</subject><subject>Visual impairment</subject><issn>1824-7288</issn><issn>1720-8424</issn><issn>1824-7288</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkk1rFTEUhgdRbK3-ARcScONmaj4mH3cjSKlaKCjYfcgkJ3dymUmuyUzp_fdmemtpXZ1w8ubhnDdv07wn-JwQJT4XwjCnLaakxYQw1pIXzSlRtGslVerlk_NJ86aUHcaMckFeNyes65RSjJw2d78gh_0A2YwoQr5NS0HlUGaY0GRi8FBmM4cUC0oe_R7C1qA53YXY7nNyiw1xiy7PkU1jaEOsDXBoMDCl8TAHi5YMUy3lEF1OE6AQkR3C6DLEt80rb8YC7x7qWXPz7fLm4kd7_fP71cXX69ZywebWdlJYqrwEJjfeOs8dtx4YZj3rJcNKCW8oBSNYTyk1VCop1aZKCfUes7Pm6oh1yez0PofJ5INOJuj7RspbbXIddQRdad73QA2RpnNc9EYpoBvc9a7n0pDK-nJk7Zd-AmchztW2Z9DnNzEMeptuteoolWId5tMDIKc_S7VWT6FYGEcToRqvKZf1I4lQq_Tjf9JdWnKsTq2qrttgzmVV0aPK5lRKBv84DMF6zYg-ZkTXjOj7jOh1jQ9P13h88i8U7C8Or7pO</recordid><startdate>20210906</startdate><enddate>20210906</enddate><creator>Santangelo, Luisa</creator><creator>Netti, Giuseppe Stefano</creator><creator>Torres, Diletta Domenica</creator><creator>Piscopo, Giovanni</creator><creator>Carbone, Vincenza</creator><creator>Losito, Luciana</creator><creator>Milella, Leonardo</creator><creator>Lasorella, Maria Luigia</creator><creator>Conti, Pasquale</creator><creator>Gagliardi, Delio</creator><creator>Chironna, Maria</creator><creator>Spadaccino, Federica</creator><creator>Bresin, Elena</creator><creator>Trabacca, Antonio</creator><creator>Ranieri, Elena</creator><creator>Giordano, Mario</creator><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-3495-2707</orcidid></search><sort><creationdate>20210906</creationdate><title>Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children</title><author>Santangelo, Luisa ; Netti, Giuseppe Stefano ; Torres, Diletta Domenica ; Piscopo, Giovanni ; Carbone, Vincenza ; Losito, Luciana ; Milella, Leonardo ; Lasorella, Maria Luigia ; Conti, Pasquale ; Gagliardi, Delio ; Chironna, Maria ; Spadaccino, Federica ; Bresin, Elena ; Trabacca, Antonio ; Ranieri, Elena ; Giordano, Mario</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Anemia</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Basal ganglia</topic><topic>Blood pressure</topic><topic>Case Report</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Coma</topic><topic>Creatinine</topic><topic>Diarrhea</topic><topic>E coli</topic><topic>Eculizumab</topic><topic>Electroencephalography</topic><topic>Enterohemorrhagic Escherichia Coli</topic><topic>Escherichia coli Infections</topic><topic>Female</topic><topic>Hemolytic uremic syndrome</topic><topic>Hemolytic-Uremic Syndrome - complications</topic><topic>Hemolytic-Uremic Syndrome - therapy</topic><topic>Humans</topic><topic>Hypokalemia</topic><topic>Hypoxia</topic><topic>Immunoglobulins</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Immunosuppressive agents</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Methylprednisolone</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Nephrology</topic><topic>Nervous system</topic><topic>Neurological complications</topic><topic>Neurological Rehabilitation</topic><topic>Neurorehabilitation</topic><topic>Neutrophils</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Peripheral nervous system</topic><topic>Plasma Exchange</topic><topic>Polyneuropathies - etiology</topic><topic>Polyneuropathies - therapy</topic><topic>Polyneuropathy</topic><topic>Potassium</topic><topic>Recovery of function</topic><topic>Rehabilitation</topic><topic>Renal replacement therapy</topic><topic>Shiga toxin</topic><topic>Shiga-Toxigenic Escherichia coli</topic><topic>Streptococcus infections</topic><topic>Substantia alba</topic><topic>Thrombocytopenia</topic><topic>Ventilators</topic><topic>Visual impairment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santangelo, Luisa</creatorcontrib><creatorcontrib>Netti, Giuseppe Stefano</creatorcontrib><creatorcontrib>Torres, Diletta Domenica</creatorcontrib><creatorcontrib>Piscopo, Giovanni</creatorcontrib><creatorcontrib>Carbone, Vincenza</creatorcontrib><creatorcontrib>Losito, Luciana</creatorcontrib><creatorcontrib>Milella, Leonardo</creatorcontrib><creatorcontrib>Lasorella, Maria Luigia</creatorcontrib><creatorcontrib>Conti, Pasquale</creatorcontrib><creatorcontrib>Gagliardi, Delio</creatorcontrib><creatorcontrib>Chironna, Maria</creatorcontrib><creatorcontrib>Spadaccino, Federica</creatorcontrib><creatorcontrib>Bresin, Elena</creatorcontrib><creatorcontrib>Trabacca, Antonio</creatorcontrib><creatorcontrib>Ranieri, Elena</creatorcontrib><creatorcontrib>Giordano, Mario</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><jtitle>Italian journal of pediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santangelo, Luisa</au><au>Netti, Giuseppe Stefano</au><au>Torres, Diletta Domenica</au><au>Piscopo, Giovanni</au><au>Carbone, Vincenza</au><au>Losito, Luciana</au><au>Milella, Leonardo</au><au>Lasorella, Maria Luigia</au><au>Conti, Pasquale</au><au>Gagliardi, Delio</au><au>Chironna, Maria</au><au>Spadaccino, Federica</au><au>Bresin, Elena</au><au>Trabacca, Antonio</au><au>Ranieri, Elena</au><au>Giordano, Mario</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children</atitle><jtitle>Italian journal of pediatrics</jtitle><addtitle>Ital J Pediatr</addtitle><date>2021-09-06</date><risdate>2021</risdate><volume>47</volume><issue>1</issue><spage>181</spage><epage>181</epage><pages>181-181</pages><artnum>181</artnum><issn>1824-7288</issn><issn>1720-8424</issn><eissn>1824-7288</eissn><abstract>The Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could usually regress after Eculizumab infusion. In contrast, peripheral nervous system (PNS) manifestations in typical HUS are very rare and, when occurring, they require a careful management of neurological sequelae and an intensive multidisciplinary neuro-rehabilitation program.
Here, we present two pediatric cases of severe and complicated typical HUS with PNS manifestations who required therapeutic treatment and an intensive multidisciplinary neuro-rehabilitation program. In both cases, PNS manifestations were followed by the recovery from typical HUS-related severe central neurological damage and manifested mainly with marked bilateral motor deficit and hyporeflexia/areflexia in the lower limbs. The peripheral polyneuropathy was treated with immunosuppressive therapy (methylprednisolone boluses, i.v. immunoglobulins, plasma exchange), followed by a prolonged intensive neuro-rehabilitation program. After 8 months of rehabilitation, both patients gained complete functional recovery.
PNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>34488831</pmid><doi>10.1186/s13052-021-01133-1</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-3495-2707</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1824-7288 |
ispartof | Italian journal of pediatrics, 2021-09, Vol.47 (1), p.181-181, Article 181 |
issn | 1824-7288 1720-8424 1824-7288 |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_730ffbe2a17a4d56ba88e2904bdb57a1 |
source | Publicly Available Content Database; PubMed Central |
subjects | Anemia Anti-Inflammatory Agents - therapeutic use Basal ganglia Blood pressure Case Report Child Child, Preschool Coma Creatinine Diarrhea E coli Eculizumab Electroencephalography Enterohemorrhagic Escherichia Coli Escherichia coli Infections Female Hemolytic uremic syndrome Hemolytic-Uremic Syndrome - complications Hemolytic-Uremic Syndrome - therapy Humans Hypokalemia Hypoxia Immunoglobulins Immunoglobulins, Intravenous - therapeutic use Immunosuppressive agents Infectious diseases Laboratories Methylprednisolone Methylprednisolone - therapeutic use Nephrology Nervous system Neurological complications Neurological Rehabilitation Neurorehabilitation Neutrophils Patients Pediatrics Peripheral nervous system Plasma Exchange Polyneuropathies - etiology Polyneuropathies - therapy Polyneuropathy Potassium Recovery of function Rehabilitation Renal replacement therapy Shiga toxin Shiga-Toxigenic Escherichia coli Streptococcus infections Substantia alba Thrombocytopenia Ventilators Visual impairment |
title | Peripheral nervous system manifestations of Shiga toxin-producing E. coli-induced haemolytic uremic syndrome in children |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T15%3A02%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Peripheral%20nervous%20system%20manifestations%20of%20Shiga%20toxin-producing%20E.%20coli-induced%20haemolytic%20uremic%20syndrome%20in%20children&rft.jtitle=Italian%20journal%20of%20pediatrics&rft.au=Santangelo,%20Luisa&rft.date=2021-09-06&rft.volume=47&rft.issue=1&rft.spage=181&rft.epage=181&rft.pages=181-181&rft.artnum=181&rft.issn=1824-7288&rft.eissn=1824-7288&rft_id=info:doi/10.1186/s13052-021-01133-1&rft_dat=%3Cproquest_doaj_%3E2574490557%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c563t-c476c28f7e379fcdf5d5cfe303b3b730886fa22ea63b222a27877899fc12ff03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2574490557&rft_id=info:pmid/34488831&rfr_iscdi=true |